Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof

US8323651B2 · kind B2 · utility

Assignees

• Abbott Laboratories · US
• Abbott GmbH & Co. KG · DE

Inventors

• Jijie Gu · Shrewsbury, US
• Chung-Ming Hsieh · Newton, US
• Zhen WU · Framingham, US
• Enrico L. DiGiammarino · Lindenhurst, US
• Feng Luo · Arlington Heights, US
• Gerard B. Fox · Barrington, US
• John E. Harlan · Lake Zurich, US
• Martin Schmidt · Frankfurt am Main, DE
• Ralf Loebbert · Speyer, DE
• Reinhold Mueller · Schifferstadt, DE
• Ulrich Ebert · Mannheim, DE
• Volker Nimmrich · Heidelberg, DE

Key dates

• Filing date: May 8, 2009
• Grant date: Dec 4, 2012
• Expiry date: Aug 17, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid β and advanced glycation-end-products.